383 related articles for article (PubMed ID: 12208152)
1. Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen.
McCarty MF
Med Hypotheses; 2002 Sep; 59(3):268-79. PubMed ID: 12208152
[TBL] [Abstract][Full Text] [Related]
2. An ezetimibe-policosanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects.
McCarty MF
Med Hypotheses; 2005; 64(3):636-45. PubMed ID: 15617880
[TBL] [Abstract][Full Text] [Related]
3. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
Prat H; Román O; Pino E
Rev Med Chil; 1999 Mar; 127(3):286-94. PubMed ID: 10436712
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
5. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase.
Singh DK; Li L; Porter TD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1020-6. PubMed ID: 16714400
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Crespo N; Illnait J; Más R; Fernández L; Fernández J; Castaño G
Int J Clin Pharmacol Res; 1999; 19(4):117-27. PubMed ID: 10939029
[TBL] [Abstract][Full Text] [Related]
7. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study.
Castaño G; Más R; Fernández L; Gámez R; Illnait J
Angiology; 2003 Jan; 54(1):25-38. PubMed ID: 12593493
[TBL] [Abstract][Full Text] [Related]
8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
9. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
[TBL] [Abstract][Full Text] [Related]
10. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
11. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects.
Greyling A; De Witt C; Oosthuizen W; Jerling JC
Br J Nutr; 2006 May; 95(5):968-75. PubMed ID: 16611388
[TBL] [Abstract][Full Text] [Related]
12. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.
Gouni-Berthold I; Berthold HK
Am Heart J; 2002 Feb; 143(2):356-65. PubMed ID: 11835043
[TBL] [Abstract][Full Text] [Related]
13. Statins reduce amyloid-beta production through inhibition of protein isoprenylation.
Ostrowski SM; Wilkinson BL; Golde TE; Landreth G
J Biol Chem; 2007 Sep; 282(37):26832-26844. PubMed ID: 17646164
[TBL] [Abstract][Full Text] [Related]
14. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
16. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
Cubeddu LX; Cubeddu RJ; Heimowitz T; Restrepo B; Lamas GA; Weinberg GB
Am Heart J; 2006 Nov; 152(5):982.e1-5. PubMed ID: 17070175
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of statins in the management of atherosclerosis.
Vaughan CJ; Gotto AM; Basson CT
J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants.
Gigleux I; Jenkins DJ; Kendall CW; Marchie A; Faulkner DA; Wong JM; de Souza R; Emam A; Parker TL; Trautwein EA; Lapsley KG; Connelly PW; Lamarche B
Br J Nutr; 2007 Dec; 98(6):1229-36. PubMed ID: 17663803
[TBL] [Abstract][Full Text] [Related]
19. [New possibilities of correction of hypercholesterolemia in patients with diabetes mellitus].
Pan'kiv VI
Lik Sprava; 2014; (5-6):56-67. PubMed ID: 25906648
[TBL] [Abstract][Full Text] [Related]
20. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial.
Dulin MF; Hatcher LF; Sasser HC; Barringer TA
Am J Clin Nutr; 2006 Dec; 84(6):1543-8. PubMed ID: 17158441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
